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A highly selective, one-pot, three-component synthesis of novel 2-alkyl-substituted 4-aminoimidazo[1,2-a]
[1,3,5]triazines has been developed. The scope of the method was explored in two dimensions, varying the
structures of trialkyl orthoesters and 2-aminoimidazoles in their reactions with cyanamide. Conveniently
performed under microwave irradiation, this method was also proved to be eﬃcient under conventional
heating. A library of 24 novel compounds was prepared in high purity using this multicomponent
approach. Molecular and crystal structures of representative molecules were studied using X-ray
crystallography.Introduction
The imidazo[1,2-a][1,3,5]triazine ring system is recognised as an
important scaﬀold in medicinal chemistry.2 The well-dened
targets for imidazo[1,2-a][1,3,5]triazines include a variety of
enzymes, such as focal adhesion kinase,3 activated Cdc42-
associated tyrosine kinase 1,4 dipeptidyl peptidase IV,5 and
phosphodiesterase 5.6 This scaﬀold has been successfully used
for the design of ligands for m-opioid7 and A1 adenosine8
receptors. The pharmacological potential of imidazo[1,2-a]
[1,3,5]triazines as anti-cancer,9 anti-viral10 and anti-diabetic11
agents has also been well documented in the literature. The
broad spectrum of biological activities of imidazo[1,2-a][1,3,5]
triazines results in ongoing demand for the development of new
practical methods for the synthesis of diversely functionalized
imidazo[1,2-a][1,3,5]triazines.
Since the rst report12 on the synthesis of the imidazo[1,2-a]
[1,3,5]triazine ring system 50 years ago, a number of methods
for the preparation of compounds with this heterocyclic core
have been reported. They typically involve triazine ringalaysia, Jalan Lagoon Selatan, Bandar
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hemistry 2018construction onto substituted imidazoles13 or, more oen, the
annulation of the imidazole ring onto substituted 1,3,5-
triazines.14 The two most common approaches utilize: (1) reac-
tions of 2-amino-1,3,5-triazines with a-haloaldehydes/ketone-
s3,8,12,14a,b or chalcones,14c and (2) intramolecular cyclisations of
2-amino-1,3,5-triazines substituted at the amino group.11,14d–f
Reports on the preparation of imidazo[1,2-a][1,3,5]triazines via
the formation of the 1,3,5-triazine ring onto imidazoles are
limited and usually utilize addition of 2-aminoimidazoles to N-
acyliso(thio)cyanates followed by the intramolecular closure of
the 1,3,5-triazine ring.13
Multicomponent reactions (MCRs) represent an eﬃcient
strategy in modern synthetic chemistry.15 Minimising the
number of synthetic steps in obtaining targeted compounds
from available starting reagents is highly desirable in the elds
of organic synthesis and drug discovery. Due to their diversity
and combinatorial potential, MCRs have become highly
appreciated tools for the preparation of libraries of compounds
for biological screening.16 However, issues surrounding chemo-
and regio-selectivity of MCRs oen pose a challenge and require
ne-tuning during method development. The need for rapid
and selective construction of biologically active compounds for
drug discovery has stimulated intense development in the use
of microwave technology. Microwave irradiation has been
eﬀectively used as an alternative source of energy, improving
eﬃciency and selectivity of MCRs.1,17,18
We have been exploring the potential for new one-pot,
multicomponent, microwave-assisted protocols for the
synthesis of azolo[1,3,5]triazines.18 Aer the development of the
MCRs utilizing aminoazoles, orthoformates and cyanamide, we
have been rening the scope of this reaction using a variety of
aminoazoles. In particular, the molecular diversity of
compounds prepared has been achieved by varying theRSC Adv., 2018, 8, 21495–21504 | 21495
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component condensation and included libraries of pyrazolo
[1,5-a][1,3,5]triazines,1,18a–c 1,2,4-triazolo[1,5-a][1,3,5]tri-
azines,18d,e and imidazo[1,2-a][1,3,5]triazines.18f Herein, we
report our attempts to further expand the scope of this MCR by
exploring its capacity to accommodate various orthoesters and
therefore, introduce a new point of diversity in the reaction
products. 2-Aminoimidazoles were selected as aminoazole
substrates for the reaction in order to explore the regio- and
chemo-selectivity of the process for these challenging substrates
bearing endocyclic nitrogen atoms of similar reactivity.Results & discussion
Synthesis
The starting materials used in our three-component reaction,
viz. 2-aminoimidazoles (1), were prepared using the previously
reported method developed by Van der Eycken's group.19 Opti-
mization of the conditions for our proposed MCR was per-
formed using a model reaction of 2-amino-4-phenylimidazole
(1a), triethyl orthoacetate, and cyanamide under microwave
irradiation (Table 1). The initial attempt to carry out this reac-
tion at 150 C for 20 min in ethyl acetate led to 4-amino-2-
methyl-7-phenylimidazo[1,2-a][1,3,5]triazine (5a) obtained in
42% yield. Despite the moderate yield, the product 5a was iso-
lated in a chromatography-free process as the sole product. We
found that the yield could be improved to 60% by performing
the reaction at 160 C for 35 min. However, despite attempts to
further increase the yields by manipulating the reaction
conditions, no improvement in the outcome was achieved.
The developed method was tested using two diﬀerent
models of microwave synthesizers: Discover SP (CEM) and
Monowave 400 (Anton Paar). The three-component reaction of
1a, triethyl orthoacetate and cyanamide under the optimizedTable 1 Optimization of conditions for the model reactiona
Entry Temperature (C) Time (min) Isolated yield (%)
1 150 20 42
2 150 30 47
3 160 20 47
4 170 20 41
5 160 30 51
6 160 35 60
7 160 40 47
8b 160 35 45
a The reaction was performed using a Discover SP CEM microwave
synthesizer with 1 mmol of 1a, 2.5 mmol of triethyl orthoacetate and
2.5 mmol of cyanamide in 2 mL of the ethyl acetate. b The reaction
was performed using 1 mmol of 1a, 3 mmol of triethyl orthoacetate
and 3 mmol of cyanamide.
21496 | RSC Adv., 2018, 8, 21495–21504conditions was conducted in both systems and resulted in the
formation of 5a in 60% and 56% yields, respectively.
Attempts to perform the reaction under reux in ethyl
acetate for 12 h led to the recovery of the starting material 1a
without traces of 5a. However, an attempt to carry out the MCR
of 1a, triethyl orthoacetate and cyanamide in the Monowave 50
(Anton Paar) reactor using sealed vessels under fast conven-
tional heating imitating the optimised microwave irradiation
conditions was successful, resulting in the 54% yield of equally
pure 5a. Therefore, we could exclude any signicant contribu-
tion of non-thermal microwave eﬀects in promoting this MCR.
In principle, the annulation of the 1,3,5-triazine ring onto
the 2-aminoimidazole 1a in the three-component reaction could
proceed with the formation of four regioisomeric structures viz.
2-aminoimidazo[1,2-a][1,3,5]triazines 2 and 3 as well as 4-ami-
noimidazo[1,2-a][1,3,5]triazines 4 and 5a (Scheme 1). However,
only one product was isolated from the MCR. The structure of
this product was assigned on the basis of spectral data and an
alternative synthesis of 5a adopting our previously reported
step-wise synthesis of azolo[1,3,5]triazines via the 1,3,5-triazine
ring annulation onto aminoazoles with a predisposed position
of the amino group on the triazine ring.20 This method con-
verted aminoazoles into formamidine intermediates via the
reaction with orthoformates and morpholine followed by the
triazine ring closing reaction of these intermediates with
cyanamide. The conversion of 2-amino-4-phenylimidazole (1a)
to the corresponding acetamidine (6) was achieved successfully
using the reaction with triethyl orthoacetate and morpholine
under microwave irradiation. The subsequent reaction of 6 with
cyanamide led to the formation of a product identical to the one
obtained from theMCR (Scheme 1). While the step-wisemethod
excluded formation of compounds 2 and 3, a ring-closing
reaction could still aﬀord compounds 4 and/or 5a. The steric
hindrance between the amino group and the phenyl ring in 4
would aﬀect the thermodynamic stability of this potential
product, therefore decreasing chances for its formation. More-
over, we could not exclude a rearrangement of 4 into 5a under
the reaction conditions. The rearrangement would proceed via
intermediate 7 via the mechanism similar to the one reported21
for the rearrangement of another fused heterocycle with the
amino-1,3,5-triazine ring. NOESY experiments performed on
the product did not revealed any through-space interactions
between the phenyl and methyl groups of the compound thus
supporting assignment of structure 5a as the MCR product. X-
ray crystal structure determinations for analogous compounds
5g and 5p (vide infra) further conrmed the regioselective
closure of the triazine ring to the more sterically accessible
endocyclic nitrogen of the imidazole.
Using the optimized conditions from the model reaction, we
explored the scope of our three-component reaction using
a variety of trialkyl orthoesters and 4-aryl substituted 2-amino-
imidazoles (1). The method was successfully applied for the
synthesis of a library of 24 new 2-alkyl-4-amino-7-arylimidazo
[1,2-a][1,3,5]triazines (5) (Table 2). The reaction was found to
proceed similarly for the full range of tested 2-aminoimidazoles
accommodating aryl substituents in the position 4 of the
imidazole ring. However, variations in the alkyl orthoester typeThis journal is © The Royal Society of Chemistry 2018
Scheme 1 Synthesis of 4-amino-2-methyl-7-phenylimidazo[1,2-a][1,3,5]triazine (5a).
Paper RSC Advancesaﬀected product yields more signicantly. In general, an
increase in length of alkyl chain substituent on compound 5 led
to a decrease of isolated yields. The yields of compounds 5a–f
and 5g–l obtained from triethyl orthoacetate and triethyl
orthopropionate, respectively, were substantially higher than
those of 5m–r and 5s–x prepared using triethyl orthobutyrate
and trimethyl orthovalerate. The decrease of yields in the
homologous series of compounds 5 could be attributed to the
relatively lower reactivity of long chain orthoesters used for their
preparation. This assumption found a conrmation in the
isolation of compounds 5 exclusively from all the reactions. No
traces of other isomers 2–4 were detected. Besides products 5,
only unreacted 2-aminoimidazoles (1) could be isolated from
the reaction mixtures.X-ray crystallography
Crystals were obtained for two representative compounds,
namely 5g and 5p, and their crystal and molecular structures
determined by X-ray crystallography. The molecular structure of
5g is shown in Fig. 1a and comprises an essentially planar nine-
membered ring with the r.m.s. deviation of the tted atoms
being 0.0129 A˚; the maximum deviations above and below the
least-square plane are found for the C2 [0.0215(8) A˚] and C9
[0.0232(9) A˚] atoms, respectively; the N41 and C71 atoms lie,
respectively, 0.0464(13) and 0.0413(13) A˚ to the same side of the
molecule.This journal is © The Royal Society of Chemistry 2018Indeed, the entire molecule, with the exception of the C2-
bound ethyl group, is essentially co-planar as seen in the
dihedral between the imidazo[1,2-a][1,3,5]triazine and phenyl
rings of 2.31(5). The ethyl group has an +anti-clinal (+ac)
disposition with respect to the fused-ring system as seen in the
torsion angle of 97.41(12) for N1–C2–C21–C22.
The crystallographic asymmetric of 5p comprises two inde-
pendent molecules, illustrated in Fig. 1b. The molecules
present features that diﬀer from those described for 5g. The
r.m.s. of the nine atoms of the fused-ring system is 0.0247 A˚
[0.0103 A˚ for the second independent molecule] with the N41
and C71 atoms lying 0.0263(15) and 0.0837(14) A˚ [0.0333(15)
and 0.0113(14) A˚] to the same side of the plane. A twist in the
molecule is evident as seen in the dihedral angle of 18.78(6)
[10.45(3)] between the rings. The C2-bound n-propyl groups
have very similar conformations with the C2–C21–C22–C23
torsion angles being 68.78(14) and 72.27(13), indicating
a syn-clinal (sc) disposition in each case. The diﬀerence is
that in the rst independent molecule, the terminal methyl
group is orientated away from the amino substituent whereas in
the second molecule, it is orientated towards the amino group.
An overlay diagram of the three molecules of 5g and 5p is shown
in Fig. 1c. The diﬀerence in the co-planarity of the aromatic
residues of 5g and 5p is clearly evident, as are the diﬀerent
orientations of the n-propyl substituents in 5p.
The molecular packing arrangements in the crystals of 5g
and 5p feature directional amino-N‒H/N(ring) hydrogenRSC Adv., 2018, 8, 21495–21504 | 21497
Table 2 Three-component synthesis of 2-alkyl-4-amino-7-arylimidazo[1,2-a][1,3,5]triazines (5)a
a The reaction was performed using a Discover SP CEM microwave synthesizer with 1 mmol of 2-aminoimidazoles (1), 2.5 mmol of trialkyl
orthoesters and 2.5 mmol of cyanamide at 160 C for 35 min in 2 mL of ethyl acetate.
RSC Advances Paperbonding. In 5g, centrosymmetrically-related molecules are
connected via amino-N‒H/N3(triazine) hydrogen bonds to
form eight-membered {/HNCN}2 synthons. The second amino-
N‒H hydrogen atom forms a hydrogen bond to the triazine-N1
atom. The result is a supramolecular layer parallel to (1 0 0) and
with a zig-zag topology with the phenyl groups lying to either
side, Fig. 2a. The layers stack along the a-axis with the primary
interactions between them being of the type p/p. The closest21498 | RSC Adv., 2018, 8, 21495–21504such interactions [3.4699(6) A˚] occur between imidazo rings,
and between phenyl rings [3.8142(7) A˚]. A view of the unit cell
contents is shown in ESI Fig. S1‡ and geometric parameters
characterizing the intermolecular interactions are given in the
gure caption.
A supramolecular layer sustained by amino-N‒H/N(ring)
hydrogen bonding is also found in the crystal of 5p. The eight-
membered {/HNCN}2 synthons arising from amino-N‒H/This journal is © The Royal Society of Chemistry 2018
Fig. 1 (a) Molecular structure of 5g and (b) molecular structures of the
two independent molecules comprising the asymmetric unit of 5p,
showing atom labelling scheme and 70% anisotropic displacement
parameters. (c) An overlay diagram of 5g (red image), the ﬁrst inde-
pendent molecule of 5p (green) and the inverted second independent
molecule of 5p (blue). The molecules have been overlapped so the
triazine rings are coincident.
Fig. 2 Supramolecular layers sustained by amino-N‒H/N(ring)
hydrogen bonding (see ESI Fig. S1‡), shown as orange dashed lines, in
the crystals of (a) 5g and (b) 5p. Non-participating hydrogen atoms
have been omitted and the carbon atoms are represented as small
spheres.
This journal is © The Royal Society of Chemistry 2018
Paper RSC AdvancesN3(triazine) hydrogen bonds is formed by each of the inde-
pendent molecules which self-associate. For the rst indepen-
dent molecule, rather than an amino-N‒H/N3(triazine)
hydrogen bond as formed by the second independent molecule
(and in the crystal of 5g), an amino-N‒H/N8(imidazo)
hydrogen bond is formed instead; the latter pairs of interactions
involve both independent molecules. As in 5g, the supramo-
lecular layer, which is approximately parallel to (1 0 1), has
a jagged topology with the 4-tolyl rings projecting to either side,
Fig. 2b. The connections between layers to consolidate the
three-dimensional architecture are of the type p(imidazo)/
p(imidazo) [3.5695(7) A˚] and p(triazine)/p(phenyl) [3.8946(7)
and 3.9224(7) A˚]. A view of the unit cell contents is shown in ESI
Fig. S2‡ with geometric parameters given in the chart caption.Conclusion
In summary, we have successfully developed a three component
reaction for the synthesis of novel 2-alkyl substituted 4-amino-
imidazo[1,2-a][1,3,5]triazines 5 using easily accessible starting
materials and a simple, catalyst- and chromatography-free
protocol. The distinct advantage of the proposed approach
was found to be high chemo- and regio-selectivity with the
exclusive formation of desired products in high purity.Experimental section
General information
Melting points (uncorrected) were determined on a Stuart™
SMP40 automatic melting point apparatus. 1H and 13C NMR
spectra were recorded on a Bruker Fourier 300 spectrometer
(300 MHz) using DMSO-d6 as a solvent and TMS as an internal
reference. Microwave-assisted reactions were carried out in the
closed vessel focused single mode using a Discover SP micro-
wave synthesizer (CEM, USA) monitoring reaction temperature
by equipped IR sensor. The model reaction was also carried out
using Monowave 400 (Anton Paar, Austria) and Monowave 50
(Anton Paar, Austria) reactors.
General method for the synthesis of 4-amino-2-alkyl-7-aryli-
midazo[1,2-a][1,3,5]triazines (5) under microwave irradiation.
The mixture of 2-aminoimidazoles (1, 1 mmol), cyanamide
(105 mg, 2.5 mmol) and trialkyl orthoesters (2.5 mmol) in ethyl
acetate (2 mL) were irradiated in a 10 mL seamless pressure vial
using a microwave system operating at maximal microwave
power up to 150W (Discover SP, CEM) or 850W (Monowave 400,
Anton Paar) at 160 C for 35 min. Aer cooling, the precipitate
was ltered, washed with ethyl acetate and recrystallised from
appropriate solvents.
4-Amino-2-methyl-7-phenylimidazo[1,2-a][1,3,5]triazine (5a).
Light yellow solid, yield 60%, mp 303–305 C (EtOH). 1H NMR
(300 MHz, DMSO-d6): d 2.38 (3H, s, CH3), 7.35 (1H, t,
3J¼ 7.4 Hz,
H-40), 7.47 (2H, t, 3J ¼ 7.5 Hz, H-30 and H-50), 7.85 (2H, d, 3J ¼
7.0 Hz, H-20 and H-60), 8.15 (1H, s, H-6), 8.35 (2H, br s, NH2).
13C
NMR (75 MHz, DMSO-d6): d 25.3 (CH3), 101.7 (C-6), 125.2 (C-20
and C-60), 127.9 (C-40), 128.7 (C-30 and C-50), 133.3 (C-10), 143.2
(C-7), 150.3 & 150.6 (C-4 and C-8a), 164.7 (C-2). Anal. Calcd forRSC Adv., 2018, 8, 21495–21504 | 21499
RSC Advances PaperC12H11N5: C, 63.99; H, 4.92; N, 31.09. Found: C, 63.82; H,
5.08; N, 30.91.
4-Amino-2-methyl-7-(4-uorophenyl)imidazo[1,2-a][1,3,5]triazine
(5b). White solid, yield 60%, mp > 350 C (EtOH). 1H NMR (300
MHz, DMSO-d6): d 2.38 (3H, s, CH3), 7.30 (2H, dd,
3JHF ¼ 8.9 Hz,
3JHH ¼ 8.9 Hz, H-30 and H-50), 7.87 (2H, dd, 4JHF ¼ 5.5 Hz, 3JHH ¼
8.9 Hz, H-20 and H-60), 8.11 (1H, s, H-6), 8.37 (2H, br s, NH2).
13C
NMR (75 MHz, DMSO-d6): d 25.3 (CH3), 101.5 (C-6), 115.7 (d,
2JCF
¼ 21.7 Hz, C-30 and C-50), 127.2 (d, 3JCF ¼ 8.3 Hz, C-20 and C-60),
129.8 (d, 4JCF ¼ 2.9 Hz, C-10), 142.3 (C-7), 150.4 & 150.6 (C-4 and
C-8a), 161.9 (d, 1JCF ¼ 244.7 Hz, C-40), 164.8 (C-2). Anal. Calcd for
C12H10FN5: C, 59.25; H, 4.14; N, 28.79. Found: C, 59.02; H,
4.30; N, 28.63.
4-Amino-2-methyl-7-(4-chlorophenyl)imidazo[1,2-a][1,3,5]triazine
(5c). Brown solid, yield 30%, mp > 350 C (EtOH). 1H NMR (300
MHz, DMSO-d6): d 2.37 (3H, s, CH3), 7.53 (2H, d,
3J¼ 8.6 Hz, H-30
and H-50), 7.9 (2H, d, 3J ¼ 8.58 Hz, H-20 and H-60), 8.16 (1H, s, H-
6), 8.38 (2H, br s, NH2).
13C NMR (75 MHz, DMSO-d6): d 25.3
(CH3), 102.1 (C-6), 126.9 (C-20 and C-60), 128.8 (C-30 and C-50),
132.1 (C-10), 132.3 (C-40), 142.1 (C-7), 150.6 & 150.4 (C-4 and C-8a),
164.9 (C-2). Anal. Calcd for C12H10ClN5: C, 55.50; H, 3.88; N,
26.97. Found: 55.42; H, 4.01; N, 26.75.
4-Amino-2-methyl-7-(4-methylphenyl)imidazo[1,2-a][1,3,5]
triazine (5d). White solid, yield 60%, mp > 350 C (EtOH). 1H
NMR (300 MHz, DMSO-d6): d 2.34 (3H, s, CH3), 2.37 (3H, s, CH3),
7.27 (2H, d, 3J ¼ 7.9 Hz, H-30 and H-50), 7.73 (2H, d, 3J ¼ 8.1 Hz,
H-20 and H-60), 8.09 (1H, s, H-6), 8.30 (2H, br s, NH2).
13C NMR
(75 MHz, DMSO-d6): d 20.8 (CH3), 25.3 (CH3), 101.1 (C-6), 125.2
(C-20 and C-60), 129.3 (C-30 and C-50), 130.5 (C-10), 137.3 (C-40),
143.4 (C-7), 150.2 & 150.5 (C-4 and C-8a), 164.5 (C-2). Anal. Calcd
for C13H13N5: C, 65.25; H, 5.48; N, 29.27. Found: 65.18; H,
5.60; N, 29.18.
4-Amino-2-methyl-7-(4-methoxyphenyl)imidazo[1,2-a][1,3,5]triazine
(5e). Light yellow solid, yield 61%,mp 338–339 C (EtOH). 1H NMR
(300 MHz, DMSO-d6): d 2.37 (3H, s, CH3), 3.80 (3H, s, OCH3), 7.03
(2H, d, 3J¼ 8.9 Hz, H-30 andH-50), 7.77 (2H, d, 3J¼ 8.9 Hz, H-20 and
H-60), 8.02 (1H, s, H-6), 8.29 (2H, br s, NH2).
13C NMR (75 MHz,
DMSO-d6): d 25.3 (CH3), 55.1 (OCH3), 100.4 (C-6), 114.2 (C-30 and C-
50), 125.8 (C-10), 126.6 (C-20 and C-60), 143.3 (C-7), 150.3 & 150.5 (C-4
and C-8a), 159.2 (C-40), 164.4 (C-2). Anal. Calcd for C13H13N5O: C,
61.17; H, 5.13; N, 27.43. Found: C, 61.05; H, 5.23; N, 27.32.
4-Amino-2-methyl-7-(4-biphenyl)imidazo[1,2-a][1,3,5]triazine (5f).
Light brown solid, yield 57%, mp > 350 C (DMF). 1H NMR (300
MHz, DMSO-d6): d 2.38 (3H, s, CH3), 7.38 (1H, t,
3J¼ 7.3 Hz, H-400),
7.49 (2H, t, 3J¼ 7.5 Hz, H-300 and H-500), 7.73 (2H, d, 3J¼ 7.1 Hz, H-
200 andH-600), 7.79 (2H, d, 3J¼ 8.4 Hz, H-30 andH-50), 7.94 (2H, d, 3J
¼ 8.4 Hz, H-20 and H-60), 8.20 (1H, s, H-6), 8.36 (2H, br s, NH2). 13C
NMR (75MHz, DMSO-d6): d 25.3 (CH3), 101.8 (C-6), 125.8 (C-30 and
C-50), 126.4 (C-300 and C-500), 127.0 (C-20 and C-60), 127.4 (C-400),
128.9 (C-200 and C-600), 132.4 (C-10), 139.5 (C-40 and C-100), 142.9 (C-
7), 150.4 & 150.6 (C-4 and C-8a), 164.7 (C-2). Anal. Calcd for
C18H15N5: C, 71.74; H, 5.02; N, 23.24. Found: C, 71.68; H, 5.11; N,
23.10.
4-Amino-2-ethyl-7-phenylimidazo[1,2-a][1,3,5]triazine (5g).
Light yellow solid, yield 53%, mp 299–301 C (EtOH). 1H NMR
(300MHz, DMSO-d6): d 1.25 (3H, t,
3J¼ 7.6 Hz, CH3), 2.66 (2H, q,
3J ¼ 7.5 Hz, CH2), 7.35 (1H, t, 3J ¼ 7.4 Hz, H-40), 7.47 (2H, t, 3J ¼21500 | RSC Adv., 2018, 8, 21495–215047.5 Hz, H-30 and H-50), 7.86 (2H, d, 3J ¼ 7.0 Hz, H-20 and H-60),
8.16 (1H, s, H-6), 8.36 (2H, br s, NH2);
13C NMR (75 MHz, DMSO-
d6): d 11.7 (CH3), 31.5 (CH2), 101.7 (C-6), 125.2 (C-20 and C-60),
127.9 (C-40), 128.7 (C-30 and C-50), 133.3 (C-10), 143.3 (C-7), 150.4
& 150.8 (C-4 and C-8a), 168.6 (C-2). Anal. Calcd for C13H13N5: C,
65.25; H, 5.48; N, 29.27. Found: C, 65.22; H, 5.52; N, 29.12.
4-Amino-2-ethyl-7-(4-uorophenyl)imidazo[1,2-a][1,3,5]triazine
(5h). White solid, yield 52%, mp 339–340 C (EtOH). 1H NMR
(300 MHz, DMSO-d6): d 1.25 (3H, t,
3J ¼ 7.6 Hz, CH3), 2.65 (2H,
q, 3J ¼ 7.5 Hz, CH2), 7.31 (2H, dd, 3JHF ¼ 8.9 Hz, 3JHH ¼ 8.9 Hz,
H-30 and H-50), 7.88 (2H, dd, 4JHF ¼ 5.5 Hz, 3JHH ¼ 8.9 Hz, H-20
and H-60), 8.12 (1H, s, H-6), 8.35 (2H, br s, NH2).
13C NMR (75
MHz, DMSO-d6): d 11.7 (CH3), 31.5 (CH2), 101.5 (C-6), 115.7 (d,
2JCF¼ 21.8 Hz, C-30 and C-50), 127.2 (d, 3JCF¼ 8.3 Hz, C-20 and C-
60), 129.9 (d, 4JCF ¼ 3.0 Hz, C-10), 142.4 (C-7), 150.4 & 150.8 (C-4
and C-8a), 161.9 (d, 1JCF ¼ 245.1 Hz, C-40), 168.7 (C-2). Anal.
Calcd for C13H12FN5: C, 60.69; H, 4.70; N, 27.22. Found: C,
60.62; H, 4.83; N, 27.11.
4-Amino-2-ethyl-7-(4-chlorophenyl)imidazo[1,2-a][1,3,5]triazine
(5i). Brown solid, yield 25%, mp 340–342 C (EtOH).1H NMR
(300MHz, DMSO-d6): d 1.24 (3H, t,
3J¼ 7.6 Hz, CH3), 2.65 (2H, q,
3J ¼ 7.5 Hz, CH2), 7.53 (2H, d, 3J ¼ 8.7 Hz, H-30 and H-50), 7.85
(2H, d, 3J ¼ 8.7 Hz, H-20 and H-60), 8.17 (1H, s, H-6), 8.36 (2H,
br s, NH2).
13C NMR (75 MHz, DMSO-d6): d 11.7 (CH3), 31.5
(CH2), 102.1 (C-6), 126.9 (C-20 and C-60), 128.8 (C-30 and C-50),
132.2 (C-10), 132.3 (C-40), 142.1 (C-7), 150.5 & 150.8 (C-4 and C-
8a), 168.8 (C-2). Anal. Calcd for C13H12ClN5: C, 57.04; H,
4.42; N, 25.59. Found: C, 56.97; H, 4.50; N, 25.49.
4-Amino-2-ethyl-7-(4-methyphenyl)imidazo[1,2-a][1,3,5]triazine
(5j). Light yellow solid, yield 61%, mp > 350 C (EtOH). 1H NMR
(300 MHz, DMSO-d6): d 1.25 (3H, t,
3J¼ 7.6 Hz, CH3), 2.34 (3H, s,
CH3), 2.65 (2H, q,
3J¼ 7.5 Hz, CH2), 7.27 (2H, d, 3J ¼ 8.0 Hz, H-3
and H-5), 7.75 (2H, d, 3J ¼ 8.1 Hz, H-20 and H-60), 8.10 (1H, s, H-
6), 8.31 (2H, br s, NH2).
13C NMR (75 MHz, DMSO-d6): d 11.7
(CH3), 20.8 (CH3), 31.5 (CH2), 101.2 (C-6), 125.2 (C-20 and C-60),
129.3 (C-30 and C-50), 130.6 (C-10), 137.3 (C-40), 143.5 (C-7), 150.3
& 150.7 (C-4 and C-8a), 168.5 (C-2). Anal. Calcd for C14H15N5: C,
66.38; H, 5.97; N, 27.65. Found: C, 66.33; H, 6.08; N, 27.58.
4-Amino-2-ethyl-7-(4-methoxyphenyl)imidazo[1,2-a][1,3,5]triazine
(5k).White solid, yield 57%,mp 328–330 C (EtOH). 1HNMR (300
MHz, DMSO-d6): d 1.24 (3H, t,
3J ¼ 7.6 Hz, CH3), 2.64 (2H, q, 3J ¼
7.6 Hz, CH2), 3.80 (3H, s, OCH3), 7.04 (2H, d,
3J¼ 8.9 Hz, H-30 and
H-50), 7.78 (2H, d, 3J ¼ 8.9 Hz, H-20 and H-60), 8.02 (1H, s, H-6),
8.29 (2H, br s, NH2).
13C NMR (75 MHz, DMSO-d6): d 11.7
(CH3), 31.4 (CH2), 100.4 (C-6), 114.2 (C-20 and C-60), 125.9 (C-40),
126.6 (C-30 and C-50), 143.4 (C-7), 150.3 & 150.6 (C-4 and C-8a),
159.2 (C-10), 168.3 (C-2). Anal. Calcd for C14H15N5O: C, 62.44; H,
5.61; N, 26.01. Found: C, 62.38; H, 5.74; N, 25.90.
4-Amino-2-ethyl-7-(4-biphenyl)imidazo[1,2-a][1,3,5]triazine (5l).
White solid, yield 49%, mp 348–350 C (DMF).1H NMR (300
MHz, DMSO-d6): d 1.26 (3H, t,
3J¼ 7.6 Hz, CH3), 2.66 (2H, q, 3J¼
7.6 Hz CH2), 7.38 (1H, t,
3J ¼ 7.3 Hz, H-400), 7.49 (2H, t, 3J ¼
7.5 Hz, H-300 and H-500), 7.73 (2H, d, 3J ¼ 7.2 Hz, H-200 and H-600),
7.79 (2H, d, 3J ¼ 8.4 Hz, H-30 and H-50), 7.95 (2H, d, 3J ¼ 8.3 Hz,
H-20 and H-60), 8.21 (1H, s, H-6), 8.36 (2H, br s, NH2).
13C NMR
(75 MHz, DMSO-d6): d 11.7 (CH3), 31.5 (CH2), 101.9 (C-6), 125.8
(C-30 and C-50), 126.4 (C-300and C-500), 127.0 (C-20 and C-60), 127.4This journal is © The Royal Society of Chemistry 2018
Paper RSC Advances(C-400), 128.9 (C-200 and C-600), 132.4 (C-10), 139.5 & 139.6 (C-40 and
C-100), 143.0 (C-7), 150.5 & 150.8 (C-4 and C-8a), 168.7 (C-2). Anal.
Calcd for C19H17N5: C, 72.36; H, 5.43; N, 22.21. Found: C, 72.31;
H, 5.52; N, 22.14.
4-Amino-2-propyl-7-phenylimidazo[1,2-a][1,3,5]triazine (5m).
Light yellow solid, yield 35%, mp 272–274 C (EtOH). 1H NMR
(300 MHz, DMSO-d6): d 0.94 (3H, t,
3J ¼ 7.4 Hz, CH3), 1.77 (2H,
m, 3J ¼ 7.4 Hz, CH2), 2.60 (2H, t, 3J¼ 7.4 Hz, CH2), 7.35 (1H, t, 3J
¼ 7.3 Hz, H-40), 7.47 (2H, t, 3J ¼ 7.5 Hz, H-30 and H-50), 7.85 (2H,
d, 3J ¼ 7.1 Hz, H-20 and H-60), 8.15 (1H, s, H-6), 8.35 (2H, br s,
NH2).
13C NMR (75 MHz, DMSO-d6): d 13.6 (CH3), 20.4 (CH2),
40.2 (CH2), 101.7 (C-6), 125.2 (C-20 and C-60), 127.9 (C-40), 128.7
(C-30 and C-50), 133.3 (C-10), 143.3 (C-7), 150.3 & 150.8 (C-4 and C-
8a), 167.6 (C-2). Anal. Calcd for C14H15N5: C, 66.38; H, 5.97; N,
27.65. Found: C, 66.31; H, 6.02; N, 27.60.
4-Amino-2-propyl-7-(4-uorophenyl)imidazo[1,2-a][1,3,5]triazine
(5n). White solid, yield 36%, mp 290–292 C (EtOH). 1H NMR
(300 MHz, DMSO-d6): d 0.94 (3H, t,
3J ¼ 7.4 Hz, CH3), 1.76 (2H,
m, 3J ¼ 7.4 Hz, CH2), 2.60 (2H, t, 3J ¼ 7.4 Hz, CH2), 7.31 (2H, dd,
3JHF ¼ 8.9 Hz, 3JHH ¼ 8.9 Hz, H-30 and H-50), 7.87 (2H, dd, 4JHF ¼
5.5 Hz, 3JHH ¼ 8.9 Hz, H-20 and H-60), 8.11 (1H, s, H-6), 8.34 (2H,
br s, NH2).
13C NMR (75 MHz, DMSO-d6): d 13.6 (CH3), 20.4
(CH2), 40.2 (CH2), 101.5 (C-6), 115.7 (d,
2JCF ¼ 21.7 Hz, C-30 and
C-50), 127.2 (d, 3JCF ¼ 8.3 Hz, C-20 and C-60), 129.9 (d, 4JCF ¼
3.5 Hz, C-10), 142.4 (C-7), 150.4 & 150.8 (C-4 and C-8a), 161.9 (d,
1JCF ¼ 244.5 Hz, C-40), 167.7 (C-2). Anal. Calcd for C14H14FN5: C,
61.98; H, 5.20; N, 25.81. Found: C, 61.92; H, 5.29; N, 25.72.
4-Amino-2-propyl-7-(4-chlorophenyl)imidazo[1,2-a][1,3,5]triazine
(5o). Light brown solid, yield 16%, mp 294–295 C (EtOH). 1H
NMR (300 MHz, DMSO-d6): d 0.94 (3H, t,
3J ¼ 7.4 Hz, CH3), 1.76
(2H, m, 3J¼ 7.4 Hz, CH2), 2.60 (2H, t, 3J¼ 7.4 Hz, CH2), 7.53 (2H,
d, 3J¼ 8.7 Hz, H-30 and H-50), 7.85 (2H, d, 3J¼ 8.9 Hz, H-20 and H-
60), 8.17 (1H, s, H-6), 8.36 (2H, br s, NH2).
13C NMR (75 MHz,
DMSO-d6): d 13.6 (CH3), 20.4 (CH2), 40.2 (CH2), 102.1 (C-6), 126.9
(C-20 and C-60), 128.8 (C-30 and C-50), 132.2 (C-10), 132.3 (C-40),
142.1 (C-7), 150.4 & 150.8 (C-4 and C-8a), 167.8 (C-2). Anal. Calcd
for C14H14ClN5: C, 58.44; H, 4.90; N, 24.34. Found: C, 58.37; H,
5.03; N, 24.22.
4-Amino-2-propyl-7-(4-methyphenyl)imidazo[1,2-a][1,3,5]triazine
(5p). Light yellow solid, yield 50%, mp 305–307 C (EtOH). 1H
NMR (300 MHz, DMSO-d6): d 0.94 (3H, t,
3J ¼ 7.4 Hz, CH3), 1.77
(2H, m, 3J ¼ 7.4 Hz, CH2), 2.34 (3H, s, CH3), 2.60 (2H, t, 3J ¼
7.4 Hz, CH2), 7.27 (2H, d,
3J¼ 7.3 Hz, H-30 and H-50), 7.75 (2H, d,
3J¼ 8.0 Hz, H-20 and H-60), 8.10 (1H, s, H-6), 8.30 (2H, br s, NH2).
13C NMR (75 MHz, DMSO-d6): d 13.6 (CH3), 20.4 (CH2), 20.8
(CH3), 40.2 (CH2), 101.2 (C-6), 125.2 (C-30 and C-50), 129.3 (C-20
and C-60), 130.6 (C-10), 137.3 (C-40), 143.5 (C-7), 150.3 & 150.7 (C-4
and C-8a), 167.5 (C-2). Anal. Calcd for C15H17N5: C, 67.39; H,
6.41; N, 26.20. Found: C, 67.32; H, 6.53; N, 26.06.
4-Amino-2-propyl-7-(4-methoxyphenyl)imidazo[1,2-a][1,3,5]triazine
(5q).White solid, yield 52%,mp 295–297 C (MeOH). 1HNMR (300
MHz, DMSO-d6): d 0.94 (3H, t,
3J ¼ 7.4 Hz, CH3), 1.76 (2H, m, 3J ¼
7.4 Hz, CH2), 2.59 (2H, t,
3J¼ 7.4 Hz, CH2), 3.80 (3H, s, OCH3), 7.04
(2H, d, 3 J ¼ 8.9 Hz, H-30 and H-50), 7.78 (2H, d, 3J ¼ 8.9 Hz, H-20
andH-60), 8.03 (1H, s, H-6), 8.30 (2H, br s, NH2).
13C NMR (75MHz,
DMSO-d6): d 13.6 (CH3), 20.4 (CH2), 40.2 (CH2), 55.1 (OCH3), 100.4
(C-6), 114.2 (C-30 and C-50), 125.9 (C-10), 126.6 (C-20 and C-60), 143.4This journal is © The Royal Society of Chemistry 2018(C-7), 150.3 & 150.6 (C-4 and C-8a), 159.2 (C-40), 167.3 (C-2). Anal.
Calcd for C15H17N5O: C, 63.59; H, 6.05; N, 24.72. Found: C, 63.52;
H, 6.20; N, 24.59.
4-Amino-2-propyl-7-(4-biphenyl)imidazo[1,2-a][1,3,5]triazine (5r).
Light brown solid, yield 40%, mp 337–338 C (DMF). 1H NMR (300
MHz, DMSO-d6): d 0.95 (3H, t,
3J ¼ 7.4 Hz, CH3), 1.78 (2H, m, 3J ¼
7.4 Hz, CH2), 2.62 (2H, t,
3J¼ 7.4 Hz, CH2), 7.38 (1H, t, 3J¼ 7.3 Hz,
H-400), 7.49 (2H, t, 3J ¼ 7.5 Hz, H-300 and H-500), 7.73 (2H, d, 3J ¼
7.2 Hz, H-200 andH-600), 7.79 (2H, d, 3J¼ 8.4 Hz, H-30 andH-50), 7.95
(2H, d, 3J¼ 8.3 Hz, H-20 and H-60), 8.21 (1H, s, H-6), 8.36 (2H, br s,
NH2).
13C NMR (75 MHz, DMSO-d6): d 13.7 (CH3), 20.4 (CH2), 40.2
(CH2), 101.9 (C-6), 125.8 (C-30 and C-50), 126.4 (C-300 and C-500),
127.0 (C-20 and C-60), 127.4 (C-400), 128.9 (C-200 and C-600), 132.4 (C-
10), 139.5 & 139.6 (C-40 and C-100), 143.0 (C-7), 150.4 & 150.8 (C-4 and
C-8a), 167.7 (C-2). Anal. Calcd for C20H19N5: C, 72.92; H, 5.81; N,
21.26. Found: C, 72.88; H, 5.94; N, 21.13.
4-Amino-2-butyl-7-phenylimidazo[1,2-a][1,3,5]triazine (5s).
Light yellow solid, yield 30%, mp 267–269 C (EtOH). 1H NMR
(300 MHz, DMSO-d6): d 0.92 (3H, t,
3J ¼ 7.3 Hz, CH3), 1.36 (2H,
m, 3J ¼ 7.4 Hz, CH2), 1.72 (2H, m, 3J ¼ 7.5 Hz, CH2), 2.62 (2H, t,
3J ¼ 7.5 Hz, CH2), 7.35 (1H, t, 3J ¼ 7.3 Hz, H-40), 7.47 (2H, t, 3J ¼
7.5 Hz, H-30 and H-50), 7.85 (2H, d, 3J ¼ 7.0 Hz, H-20 and H-60),
8.15 (1H, s, H-6), 8.35 (2H, br s, NH2).
13C NMR (75 MHz, DMSO-
d6): d 13.7 (CH3), 21.7 (CH2), 29.3 (CH2), 37.9 (CH2), 101.7 (C-6),
125.2 (C-20 and C-60), 127.9 (C-40), 128.7 (C-30 and C-50), 133.3 (C-
10), 143.3 (C-7), 150.3 & 150.8 (C-4 and C-8a), 167.8 (C-2). Anal.
Calcd for C15H17N5: C, 67.39; H, 6.41; N, 26.20. Found: C, 67.32;
H, 6.55; N, 26.04.
4-Amino-2-butyl-7-(4-uorophenyl)imidazo[1,2-a][1,3,5]triazine
(5t). White solid, yield 29%, mp 296–298 C (EtOH). 1H NMR
(300 MHz, DMSO-d6): d 0.92 (3H, t,
3J ¼ 7.3 Hz, CH3), 1.36 (2H,
m, 3J ¼ 7.4 Hz, CH2), 1.72 (2H, m, 3J ¼ 7.5 Hz, CH2), 2.62 (2H, t,
3J¼ 7.5 Hz, CH2), 7.31 (2H, dd, 3JHF¼ 8.9 Hz, 3JHH¼ 8.9 Hz, H-30
and H-50), 7.88 (2H, dd, 4JHF¼ 5.6 Hz, 3JHH¼ 8.9 Hz, H-20 and H-
60), 8.12 (1H, s, H-6), 8.34 (2H, br s, NH2).
13C NMR (75 MHz,
DMSO-d6): d 13.8 (CH3), 21.7 (CH2), 29.3 (CH2), 37.9 (CH2), 101.5
(C-6), 115.7 (d, 2JCF ¼ 21.7 Hz, C-30 and C-50), 127.2 (d, 3JCF ¼
8.3 Hz, C-20 and C-60), 129.9 (d, 4JCF ¼ 3.0 Hz, C-10), 142.4 (C-7),
150.4 & 150.8 (C-4 and C-8a), 161.9 (d, 1JCF ¼ 244.8 Hz, C-40),
167.9 (C-2). Anal. Calcd for C15H16FN5: C, 63.14; H, 5.65; N,
24.55. Found: C, 63.05; H, 5.77; N, 24.42.
4-Amino-2-butyl-7-(4-chlorophenyl)imidazo[1,2-a][1,3,5]triazine
(5u). Light brown solid, yield 11%, mp 287–288 C (EtOH). 1H
NMR (300 MHz, DMSO-d6): d 0.91 (3H, t,
3J ¼ 7.3 Hz, CH3), 1.35
(2H, m, 3J ¼ 7.4 Hz, CH2), 1.72 (2H, m, 3J ¼ 7.5 Hz, CH2), 2.62
(2H, t, 3J ¼ 7.5 Hz, CH2), 7.53 (2H, d, 3J ¼ 8.6 Hz, H-30 and H-50),
7.84 (2H, d, 3J ¼ 8.6 Hz, H-20 and H-60), 8.16 (1H, s, H-6), 8.36
(2H, br s, NH2).
13C NMR (75 MHz, DMSO-d6): d 13.7 (CH3), 21.7
(CH2), 29.3 (CH2), 37.9 (CH2), 102.1 (C-6), 126.9 (C-20 and C-60),
128.8 (C-30 and C-50), 132.2 & 132.33 (C-10 and C-40), 142.1 (C-7),
150.4 & 150.8 (C-4 and C-8a), 168.1 (C-2). Anal. Calcd for
C15H16ClN5: C, 59.70; H, 5.34; N, 23.21. Found: C, 59.63; H,
5.41; N, 23.15.
4-Amino-2-butyl-7-(4-methylphenyl)imidazo[1,2-a][1,3,5]triazine
(5v). Light yellow solid, yield 25%, mp 287–289 C (EtOH). 1H
NMR (300 MHz, DMSO-d6): d 0.92 (3H, t,
3J ¼ 7.3 Hz, CH3), 1.36
(2H, m, 3J ¼ 7.4 Hz, CH2), 1.72 (2H, m, 3J ¼ 7.5 Hz, CH2), 2.34RSC Adv., 2018, 8, 21495–21504 | 21501
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3J ¼ 7.5 Hz, CH2), 7.27 (2H, d, 3J ¼
7.9 Hz, H-30 and H-50), 7.74 (2H, d, 3J ¼ 8.1 Hz, H-20 and H-60),
8.09 (1H, s, H-6), 8.30 (2H, br s, NH2).
13C NMR (75 MHz, DMSO-
d6): d 13.7 (CH3), 20.8 (CH3), 21.7 (CH2), 29.3 (CH2), 37.9 (CH2),
101.2 (C-6), 125.2 (C-20 and C-60), 129.3 (C-30 and C-50), 130.5 (C-
10), 137.3 (C-40), 143.5 (C-7), 150.3 & 150.7 (C-4 and C-8a), 167.7
(C-2). Anal. Calcd for C16H19N5: C, 68.30; H, 6.81; N, 24.89.
Found: C, 68.24; H, 6.90; N, 24.81.
4-Amino-2-butyl-7-(4-methoxyphenyl)imidazo[1,2-a][1,3,5]triazine
(5w). Light yellow solid, yield 25%, mp 279–281 C (MeOH). 1H
NMR (300 MHz, DMSO-d6): d 0.92 (3H, t,
3J ¼ 7.3 Hz, CH3), 1.36
(2H,m, 3J¼ 7.4 Hz, CH2), 1.72 (2H,m, 3J¼ 7.5 Hz, CH2), 2.62 (2H,
t, 3J¼ 7.5 Hz, CH2), 3.81 (3H, s, OCH3), 7.04 (2H, d, 3J¼ 8.9 Hz, H-
30 andH-50), 7.78 (2H, d, 3J¼ 8.8 Hz, H-20 andH-60), 8.03 (1H, s, H-
6), 8.30 (2H, br s, NH2).
13C NMR (75 MHz, DMSO-d6): d 13.8
(CH3), 21.7 (CH2), 29.3 (CH2), 37.9 (CH2), 55.1 (OCH3), 100.4 (C-6),
114.2 (C-30 and C-50), 125.9 (C-10), 126.6 (C-20 and C-60), 143.4 (C-
7), 150.3 & 150.6 (C-4 and C-8a), 159.2 (C-40), 167.6 (C-2). Anal.
Calcd for C16H19N5O: C, 64.63; H, 6.44; N, 23.55. Found: C, 64.55;
H, 6.54; N, 23.43.
4-Amino-2-butyl-7-(4-biphenyl)imidazo[1,2-a][1,3,5]triazine (5x).
Light brown solid, yield 43%, mp 327–329 C (DMF). 1H NMR (300
MHz, DMSO-d6): d 0.92 (3H, t,
3J ¼ 7.3 Hz, CH3), 1.37 (2H, m, 3J ¼
7.4 Hz, CH2), 1.73 (2H,m,
3J¼ 7.5Hz, CH2), 2.63 (2H, t, 3J¼ 7.5 Hz,
CH2), 7.38 (1H, t,
3J ¼ 7.3 Hz, H-400), 7.49 (2H, t, 3J ¼ 7.5 Hz, H-300
andH-500), 7.73 (2H, d, 3J¼ 7.5 Hz, H-200 andH-600), 7.79 (2H, d, 3J¼
8.4 Hz, H-30 and H-50), 7.94 (2H, d, 3J¼ 8.4 Hz, H-20 and H-60), 8.20
(1H, s, H-6), 8.36 (2H, br s, NH2).
13C NMR (75 MHz, DMSO-d6):
d 13.7 (CH3), 21.7 (CH2), 29.3 (CH2), 37.9 (CH2), 101.8 (C-6), 125.8
(C-30 and C-50), 126.4 (C-300 and C-500), 127.0 (C-20 and C-60), 127.4
(C-400), 128.9 (C-200 and C-600), 132.4 (C-10), 139.5 (C-40 and C-100),
143.0 (C-7), 150.4 & 150.7 (C-4 and C-8a), 167.9 (C-2). Anal. Calcd
for C21H21N5: C, 73.44; H, 6.16; N, 20.39. Found: C, 73.38; H,
6.26; N, 20.31.
Synthesis of 4-amino-2-methyl-7-phenylimidazo[1,2-a][1,3,5]
triazine (5a) using Monowave 400 (Anton Paar) microwave
synthesizer. The mixture of 2-amino-4-phenyl-1H-imidazole (1a,
159 mg, 1 mmol), cyanamide (105 mg, 2.5 mmol) and triethyl
orthoacetate (0.46 mL, 2.5 mmol) in ethyl acetate (2 mL) were
irradiated in a 10 mL seamless pressure vial using a microwave
system operating at maximal microwave power up to 850 W
(Monowave 400, Anton Paar) at 160 C for 35 min. Aer cooling,
the precipitate was ltered and washed with ethyl acetate to give
5a in the 56% yield.
Synthesis of 4-amino-2-methyl-7-phenylimidazo[1,2-a][1,3,5]
triazine (5a) via heating in a sealed vessel. The mixture of 2-
amino-4-phenyl-1H-imidazole (1a, 159 mg, 1 mmol), cyanamide
(105 mg, 2.5 mmol) and triethyl orthoacetate (0.46 mL, 2.5
mmol) in ethyl acetate (2 mL) were heated in a 10 mL seamless
pressure vial in an enclosed system (Monowave 50, Anton Paar)
at 160 C for 35 min. Aer cooling, the precipitate was ltered to
obtain a compound, which was identical to 5a prepared under
microwave irradiation. Yield 54%.
Step-wise approach for the synthesis of 4-amino-2-methyl-7-
phenylimidazo[1,2-a][1,3,5]triazine (5a)
N0,N0-Morpholino-N-[3(5)-phenylimidazolo-5(3)yl acetamidine (6).
A mixture of 2-amino-1H-imidazole 1a (159 mg, 1 mmol) with21502 | RSC Adv., 2018, 8, 21495–21504triethyl orthoacetate (0.46 mL, 2.5 mmol) and morpholine (0.22
mL, 2.5 mmol) in ethyl acetate (2 mL) were irradiated in a 10 mL
seamless pressure vial using the Discover SP (CEM) microwave
system operating at maximal microwave power up to 150 W at
160 C for 35 min. Aer cooling, the precipitate was ltered and
recrystallised from EtOH to give pure formamidine 6. Light yellow
solid, yield 34%, mp 217–219 C (EtOH).1H NMR (300 MHz,
DMSO-d6): d 2.28 (3H, s, CH3), 3.55–3.56 (4H,m, (CH2)2), 3.62–3.65
(4H,m, (CH2)2), 7.10 (1H, t,
3J¼ 7.3 Hz, H-40), 7.22 (1H, s, CH), 7.29
(2H, t, 3J¼ 7.7 Hz, H-30 andH-50), 7.66 (2H, d, 3J¼ 6.9 Hz, H-20 and
H-60), 11.08 & 11.44 (1H, br s, NH). Anal. Calcd for C15H18N4O: C,
66.64; H, 6.71; N, 20.73. Found: C, 66.46; H, 6.94; N, 20.55.
4-Amino-2-methyl-7-phenylimidazo[1,2-a][1,3,5]triazine (5a). A
mixture of 6 (270 mg, 1 mmol) with cyanamide (105 mg, 2.5
mmol) in ethyl acetate (2 mL) were irradiated in a 10 mL
seamless pressure vial using the Discover SP (CEM) microwave
system operating at maximal microwave power up to 150 W at
160 C for 35 min. Aer cooling, the precipitate was ltered to
obtain a compound, which was identical to 5a prepared using
the multicomponent reaction. Yield 43%.
X-Ray crystallographic analysis. Intensity data for 5g and 5p
were measured at 100 K on an Rigaku/Oxford Diﬀraction Xta-
LAB Synergy diﬀractometer (Dualex, AtlasS2) tted with CuKa
radiation (l ¼ 1.54178 A˚) so that qmax ¼ 67.1. Data reduction
and Gaussian absorption corrections were by standard
methods.22 The structures were solved by direct-methods23 and
rened on F2 (ref. 24) with anisotropic displacement parame-
ters, C-bound H atoms in the riding model approximation and
N-bound H atoms rened with N–H ¼ 0.88  0.01 A˚. A
weighting scheme of the form w ¼ 1/[s2(Fo2) + (aP)2 + bP] where
P ¼ (Fo2 + 2Fc2)/3 was introduced in each case. The molecular
structure diagrams showing 70% probability displacement
ellipsoids were generated by ORTEP for Windows25 and the
packing diagrams with DIAMOND.26 Additional data analysis
was made with PLATON.27
Crystal data for 4-amino-2-ethyl-7-phenylimidazo[1,2-a][1,3,5]
triazine (5g). M ¼ 239.28, orthorhombic, Pccn, a ¼ 16.6173(2),
b¼ 11.17070(10), c¼ 12.4074(2) A˚, V¼ 2303.15(5) A˚3, Z¼ 8, Dx¼
1.380 g cm3, F(000) ¼ 1008, m ¼ 0.709 mm1, no. rens meas.
¼ 14 762, no. unique rens¼ 2060 (Rint¼ 0.026), no. rens with
I $ 2s(I) ¼ 1935, no. parameters ¼ 170, R(obs. data) ¼ 0.032,
wR2(all data) ¼ 0.085. CCDC deposition number: 1840247.
Crystal data for 4-amino-2-propyl-7-(4-methyphenyl)imidazo
[1,2-a][1,3,5]triazine (5p). M ¼ 267.33, triclinic, P1, a ¼
10.7534(2), b ¼ 11.8995(2), c ¼ 12.1124(3) A˚, a ¼ 71.918(2), b ¼
68.962(2), g ¼ 78.712(2), V ¼ 1368.93(5) A˚3, Z ¼ 4, Dx ¼
1.297 g cm3, F(000) ¼ 568, m ¼ 0.650 mm1, no. rens meas. ¼
32 816, no. unique rens ¼ 4893 (Rint ¼ 0.029), no. rens with I
$ 2s(I) ¼ 4530, no. parameters ¼ 377, R(obs. data) ¼ 0.034,
wR2(all data) ¼ 0.092. CCDC deposition number: 1840248.Conﬂicts of interest
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